FLEBOGAMMA 10% SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

IMMUNOGLOBULIN (HUMAN)

可用日期:

INSTITUTO GRIFOLS S.A.

ATC代码:

J06BA02

INN（国际名称）:

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM.

剂量:

100MG

药物剂型:

SOLUTION

组成:

IMMUNOGLOBULIN (HUMAN) 100MG

给药途径:

INTRAVENOUS

每包单位数:

50/100/200ML

处方类型:

Schedule D

治疗领域:

SERUMS

產品總結:

Active ingredient group (AIG) number: 0106267005; AHFS:

授权状态:

APPROVED

授权日期:

2017-08-17

产品特点

_ _
_ _
_Page 1 of 30_
PRODUCT MONOGRAPH
FLEBOGAMMA
® 10%
Immune Globulin Intravenous (Human)
Solution for infusion, 100 mg/mL
Passive immunizing agent
Immune sera and immunoglobulins: immunoglobulins, normal human, for
intravascular
administration. ATC code: J06BA02
Manufactured by:
Instituto Grifols, S.A.
Can Guasc, 2 - Parets del Vallès
E-08150 Barcelona
Spain
Imported and Distributed by:
Grifols Canada Ltd.
5060 Spectrum Way
Suite 405
Mississauga, Ontario
L4W 5N5
Date of Approval:
August 17, 2017
Submission Control No: 194291
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
...............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 13
STORAGE AND STABILITY
.........................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
......................................................................
16
DOSAGE FORMS, COMPOSIT